0000899243-20-026443.txt : 20200929 0000899243-20-026443.hdr.sgml : 20200929 20200929081838 ACCESSION NUMBER: 0000899243-20-026443 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20200925 FILED AS OF DATE: 20200929 DATE AS OF CHANGE: 20200929 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: INGRAM ROBERT ALEXANDER CENTRAL INDEX KEY: 0001219890 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39200 FILM NUMBER: 201206244 MAIL ADDRESS: STREET 1: 280 S. MANGUM STREET STREET 2: SUITE 350 CITY: DURHAM STATE: NC ZIP: 27701 FORMER NAME: FORMER CONFORMED NAME: INGRAM ROBERT A DATE OF NAME CHANGE: 20030222 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Black Diamond Therapeutics, Inc. CENTRAL INDEX KEY: 0001701541 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 139 MAIN STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-417-5868 MAIL ADDRESS: STREET 1: 139 MAIN STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: Aset Therapeutics, Inc. DATE OF NAME CHANGE: 20170321 3 1 doc3.xml FORM 3 SUBMISSION X0206 3 2020-09-25 1 0001701541 Black Diamond Therapeutics, Inc. BDTX 0001219890 INGRAM ROBERT ALEXANDER C/O BLACK DIAMOND THERAPEUTICS, INC. 139 MAIN STREET CAMBRIDGE MA 02142 1 0 0 0 Exhibit 24 - Power of Attorney /s/ Brent Hatzis-Schoch, as Attorney-in-Fact 2020-09-29 EX-24 2 attachment1.htm EX-24 DOCUMENT
                                                                      Exhibit 24
                               POWER OF ATTORNEY

     Know all by these presents, that the undersigned hereby constitutes and
appoints each of Brent Hatzis-Schoch, Marishka DeToy, Carolyn Ward and Karin
Yoo, signing singly, the undersigned's true and lawful attorney-in-fact to:

     (1)  execute for and on behalf of the undersigned, in the
          undersigned's capacity as an officer and/or director of Black Diamond
          Therapeutics, Inc., a Delaware corporation (the "Company"), (i) Form
          ID, including any attached documents, to effect the assignment of
          codes to the undersigned to be used in the transmission of information
          to the United States Securities and Exchange Commission using the
          EDGAR System, (ii) Forms 3, 4 and 5, (iii) Schedule 13D, (iv) Schedule
          13G and (v) amendments of each thereof, in accordance with Section
          16(a) of the Securities Exchange Act of 1934, as amended, and the
          rules thereunder;

     (2)  do and perform any and all acts for and on behalf of the
          undersigned which may be necessary or desirable to complete and
          execute any such Form 3, 4 or 5, Schedule 13D. Schedule 13G or any
          amendments thereto and timely file such form with the United States
          Securities and Exchange Commission and any stock exchange or similar
          authority; and

     (3)  take any other action of any type whatsoever in connection
          with the foregoing which, in the opinion of such attorney-in-fact, may
          be of benefit to, in the best interest of, or legally required by, the
          undersigned, it being understood that the documents executed by such
          attorney-in-fact on behalf of the undersigned pursuant to this Power
          of Attorney shall be in such form and shall contain such terms and
          conditions as such attorney-in-fact may approve in such attorney-in-
          fact's discretion.

     The undersigned hereby grants to each such attorney-in-fact full power and
authority to do and perform any and every act and thing whatsoever requisite,
necessary, or proper to be done in the exercise of any of the rights and powers
herein granted, as fully to all intents and purposes as the undersigned might or
could do if personally present, with full power of substitution or revocation,
hereby ratifying and confirming all that such attorney-in-fact, or such
attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be
done by virtue of this Power of Attorney and the rights and powers herein
granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in
serving in such capacity at the request of the undersigned, are not assuming,
nor is the Company assuming, any of the undersigned's responsibilities to comply
with Section 16 or Regulation 13D-G of the Securities Exchange Act of 1934, as
amended. The undersigned hereby agrees to indemnify the attorney-in-fact and the
Company from and against any demand, damage, loss, cost or expense arising from
any false or misleading information provided by the undersigned to the attorney-
in-fact.

     This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 3, 4 and 5 with respect to the
undersigned's holdings of and transactions in securities issued by the Company,
unless earlier revoked by the undersigned in a signed writing delivered to the
foregoing attorneys-in-fact. This Power of Attorney may be filed with the
United States Securities and Exchange Commission as a confirming statement of
the authority granted herein. This Power of Attorney supersedes any prior power
of attorney in connection with the undersigned's capacity as an officer and/or
director of the Company. This Power of Attorney shall expire as to any
individual attorney-in-fact if such attorney-in-fact ceases to be an executive
officer of the Company.


     IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of September 29, 2020.

                                                  /s/ Robert A. Ingram
                                                  ----------------------
                                                  Robert A. Ingram